TNXP - Tonix Pharmaceuticals Holding Corp.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.10
-0.03 (-0.96%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.13
Open3.20
Bid2.95 x 1000
Ask3.45 x 800
Day's Range3.00 - 3.21
52 Week Range2.70 - 4.99
Volume27,856
Avg. Volume67,472
Market Cap26.228M
Beta2.52
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Associated Press10 days ago

    Tonix: 1Q Earnings Snapshot

    The New York-based company said it had a loss of 88 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...

  • Benzinga23 days ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Heat Biologics Inc (NASDAQ: HTBX ) stock was trading ...

  • Zacks Small Cap Research2 months ago

    TNXP: Phase 3 Trial in PTSD Nearing 50% Enrollment; Interim Analysis in 3Q18

    In 2017, Tonix (TNXP) announced the first patient was enrolled in the Phase 3 HONOR study of TNX-102 SL 5.6 mg for the treatment of posttraumatic stress disorder (PTSD, NCT03062540). The HONOR trial is a 12-week, multicenter, randomized, double blind, placebo controlled, fixed dose study of 5.6 mg TNX-102 SL (2 x 2.8 mg tablets) taken at bedtime. Approximately 550 subjects who have served in the military and meet a diagnosis of PTSD according to the Clinician-Administered PTSD Scale (CAPS-5) for DSM-5 are eligible to enroll.

  • Associated Press2 months ago

    Tonix reports 4Q loss

    The New York-based company said it had a loss of 71 cents per share. Losses, adjusted for non-recurring costs, were 67 cents per share. For the year, the company reported that its loss narrowed to $21.1 ...

  • Benzinga4 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP ...

  • Zacks Small Cap Research4 months ago

    TNXP: Ready to File IND to Study TNX 102-SL in Agitation in Alzheimer’s Disease

    Tonix Pharmaceutical Holdings Corp. (TNXP) recently announced the company had completed a pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding the use of TNX-102 SL (cyclobenzaprine HCl sublingual tablet) for agitation in Alzheimer’s disease (AD). Agitated behaviors (e.g., irritability, restlessness, aggression) are a significant issue in patients with AD.

  • What Are Analysts Saying About Tonix Pharmaceuticals Holding Corp’s (NASDAQ:TNXP) Future?
    Simply Wall St.5 months ago

    What Are Analysts Saying About Tonix Pharmaceuticals Holding Corp’s (NASDAQ:TNXP) Future?

    The most recent earnings announcement Tonix Pharmaceuticals Holding Corp’s (NASDAQ:TNXP) released in September 2017 revealed company earnings became less negative compared to the previous year’s level as a result ofRead More...

  • Zacks Small Cap Research5 months ago

    TNXP: The Origin of the Smallpox Vaccine and the Implications for TNX-801

    Tonix Pharmaceutical Holdings Corp. (TNXP) announced earlier this year that the company had successfully synthesized a smallpox-preventing vaccine. While always thought to be based on a cowpox virus, new research has shown that the horsepox virus may be the ancestor of the smallpox vaccine, thus lending further support to Tonix’s use of a horsepox virus for a new smallpox vaccine. Edward Jenner was a British physician who is known as the father of modern vaccination.

  • Associated Press7 months ago

    Tonix reports 3Q loss

    On a per-share basis, the New York-based company said it had a loss of 77 cents. Losses, adjusted for non-recurring costs, were 70 cents per share. The company's shares closed at $3.66. A year ago, they ...

  • Tonix Pharmaceuticals Holding Corp’s (TNXP): From Cash To Ash?
    Simply Wall St.8 months ago

    Tonix Pharmaceuticals Holding Corp’s (TNXP): From Cash To Ash?

    Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) announced a loss of -$24.90M in its most recent earnings update. Although some investors expected this, their belief in the path to profitability for TNXPRead More...

  • Zacks Small Cap Research9 months ago

    TNXP: Patient Enrollment Continues for Phase 3 Study of Tonmya® in PTSD; Interim Analysis Expected in 1H18

    Tonix (TNXP) is a pharmaceutical company focused on the development of products to address major public health challenges. The company’s lead product, Tonmya® (TNX-102 SL), is currently being developed as a treatment for posttraumatic stress disorder (PTSD). A Phase 3 clinical trial in military-related PTSD (the HONOR study) was initiated in the first quarter of 2018, and we anticipate an unblinded interim analysis taking place in the first half of 2018.

  • Associated Press9 months ago

    Tonix reports 2Q loss

    On a per-share basis, the New York-based company said it had a loss of 65 cents. The company's shares closed at $3.15. A year ago, they were trading at $25.60. _____ This story was generated by Automated ...